Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00354081 | WENBIT - Western Norway B Vitamin Intervention Trial | PHASE3 | COMPLETED | 3,096 | — | — | Apr 1, 1999 | Feb 1, 2008 | Jul 12, 2013 | 2 | Norway |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | folic acid (0.8 mg) plus vitamin B12 (0.4 mg) and vitamin B6 (40 mg) |
| 2 | ACTIVE_COMPARATOR | folic acid (0.8 mg) plus vitamin B12 (0.4 mg) |
| 3 | ACTIVE_COMPARATOR | vitamin B6 (40 mg) |
| 4 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine) | DRUG | folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day |
| folic acid, vitamin B12 (cyanocobalamin) | DRUG | folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day |
| vitamin B6 (pyridoxine) | DRUG | vitamin B6 40 mg, in a capsule, taken orally once a day |
| placebo | DRUG | placebo, in a capsule, taken orally once a day |
Inclusion Criteria: * adults ≥ 18 years able to give informed consent * patients prepared to undergo long-term follow-up * patients with and without significant coronary artery disease (CAD) who have undergone coronary angiography just before inclusion Exclusion Criteria: * patients who are not a...